Skip to main content

Advertisement

Table 1 Classical clinical chemistry parameters following cholestyramine administration in placebo- or moxifloxacin-treated subjects

From: Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine

Subject# Treatment type ALT (U/L) baseline ALT (U/L) peak Peak ALT(ULN) AST (ULN) ALP (ULN) Total bilirubin (ULN)
1 Placebo 16 273 6.1 1.8 1.0 0.6
2 Placebo 19 320 9.4 3.6 0.7 0.4
3 Placebo 15 967 28.4 10.9 0.9 0.6
4 Placebo 18 119 3.5 1.9 0.7 0.5
5 Placebo 16 145 4.3 2.6 0.6 0.8
6 Placebo 12 146 4.3 2.6 0.6 0.4
7 Moxifloxacin 33 164 3.6 1.8 1.1 0.3
8 Moxifloxacin 32 173 3.8 2.0 0.6 0.5
9 Moxifloxacin 30 229 5.1 2.7 1.4 0.9
10 Moxifloxacin 14 142 3.2 1.5 0.7 0.9
11 Moxifloxacin 20 136 4.0 1.9 0.8 0.4
  1. For ALT, both absolute peak value and ULN have been included. For AST, ALP, and total Bilirubin only ULN have been included.